Banner Publications MH200828 N141

Publications

Results found: 95

Showing results: 51 - 95

Pharmacotherapy

Exposure-Response Assessment of Enzalutamide and Its Major Metabolites in a Real-World Cohort of Patients with Metastatic Castration-Resistant Prostate Cancer.

01-12-2019
Nature communications

The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact.

20-11-2019
Pharmaceutical research

Exposure to Docetaxel in the Elderly Patient Population: a Population Pharmacokinetic Study.

15-11-2019
Clinical genitourinary cancer

Second-Line Cabazitaxel Treatment in Castration-Resistant Prostate Cancer Clinical Trials Compared to Standard of Care in CAPRI: Observational Study in the Netherlands.

01-10-2019
Clinical genitourinary cancer

Efficacy, Tolerance, and Plasma Levels of Abiraterone and Its Main Metabolites in a Patient With Metastatic Castration-resistant Prostate Cancer With a Hepatic Transplant.

01-10-2019
Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Assessment of Simplified Methods for Quantification of 18F-FDHT Uptake in Patients with Metastatic Castration-Resistant Prostate Cancer.

01-09-2019
Endocrine-related cancer

Androgen receptor enhancer usage and the chromatin regulatory landscape in human prostate cancers.

01-05-2019
Cancer cell

CHD1 Loss Alters AR Binding at Lineage-Specific Enhancers and Modulates Distinct Transcriptional Programs to Drive Prostate Tumorigenesis.

15-04-2019
Drugs & aging

Age-Associated Hematological Toxicity in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Docetaxel in Clinical Practice.

01-04-2019
Cancer medicine

Neutropenia and docetaxel exposure in metastatic castration-resistant prostate cancer patients: A meta-analysis and evaluation of a clinical cohort.

01-04-2019
Clinical genitourinary cancer

Plasma Levels of Enzalutamide and Its Main Metabolites in a Patient With Metastatic Castration-resistant Prostate Cancer Undergoing Hemodialysis.

01-04-2019
The Journal of urology

Concurrent Radiotherapy and Panitumumab after Lymph Node Dissection and Induction Chemotherapy for Invasive Bladder Cancer.

01-03-2019
Prostate cancer and prostatic diseases

Impact of age on exposure to oral antiandrogen therapies in clinical practice.

01-03-2019
Head & neck

HLA class II expression on tumor cells and low numbers of tumor-associated macrophages predict clinical outcome in oropharyngeal cancer.

01-02-2019
Life science alliance

Optimized ChIP-seq method facilitates transcription factor profiling in human tumors.

01-02-2019
JCI insight

Frequent clonal relations between metastases and non-index prostate cancer lesions.

24-01-2019
Nature communications

Integrative epigenetic taxonomy of primary prostate cancer.

21-11-2018
Endocrine-related cancer

Enzalutamide therapy for advanced prostate cancer: efficacy, resistance and beyond.

31-10-2018
Molecular oncology

Loss of androgen receptor signaling in prostate cancer-associated fibroblasts (CAFs) promotes CCL2- and CXCL8-mediated cancer cell migration.

01-08-2018
Endocrine-related cancer

Androgen receptor moonlighting in the prostate cancer microenvironment.

01-06-2018
Oncogene

Endogenous androgen receptor proteomic profiling reveals genomic subcomplex involved in prostate tumorigenesis.

18-01-2018
Oncotarget

Prognostic factors in men with metastatic castration-resistant prostate cancer treated with cabazitaxel.

05-12-2017
Oncotarget

The adaptive immune system promotes initiation of prostate carcinogenesis in a human c-Myc transgenic mouse model.

07-11-2017
Clinical genitourinary cancer

The Contemporary Use of Radium-223 in Metastatic Castration-resistant Prostate Cancer.

06-09-2017
The Lancet. Oncology

Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial.

01-04-2017
Clinical cancer research : an official journal of the American Association for Cancer Research

Effects of Budesonide on Cabazitaxel Pharmacokinetics and Cabazitaxel-Induced Diarrhea: A Randomized, Open-Label Multicenter Phase II Study.

01-04-2017
Neoplasia (New York, N.Y.)

Randomized Phase III Study to Assess Efficacy and Safety of Adjuvant CAPOX with or without Bevacizumab in Patients after Resection of Colorectal Liver Metastases: HEPATICA study.

01-02-2017
Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1.

01-09-2016
Oncology

Enzalutamide as a Fourth- or Fifth-Line Treatment Option for Metastatic Castration-Resistant Prostate Cancer.

22-08-2016
Urology case reports

The Effects of Enzalutamide Monotherapy on Multiparametric 3T MR Imaging in Prostate Cancer.

01-07-2016
Oncotarget

mTOR pathway activation is a favorable prognostic factor in human prostate adenocarcinoma.

31-05-2016
Genomics data

Androgen receptor DNA binding and chromatin accessibility profiling in prostate cancer.

01-03-2016
World journal of urology

Neoadjuvant induction dose-dense MVAC for muscle invasive bladder cancer: efficacy and safety compared with classic MVAC and gemcitabine/cisplatin.

01-02-2016
The Prostate

Prognostic parameters for response to enzalutamide after docetaxel and abiraterone treatment in metastatic castration-resistant prostate cancer patients; a possible time relation.

01-01-2016
European journal of cancer (Oxford, England : 1990)

The influence of prior novel androgen receptor targeted therapy on the efficacy of cabazitaxel in men with metastatic castration-resistant prostate cancer.

01-11-2015
EMBO molecular medicine

Androgen receptor profiling predicts prostate cancer outcome.

01-11-2015
Clinical genitourinary cancer

Neoadjuvant taxane-based combination chemotherapy in patients with advanced penile cancer.

01-02-2015
BJU international

Occult lymph node metastases in patients with carcinoma invading bladder muscle: incidence after neoadjuvant chemotherapy and cystectomy vs after cystectomy alone.

01-07-2014
The Lancet. Oncology

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial.

01-06-2014
Urology

Induction chemotherapy followed by surgery in node positive bladder cancer.

01-01-2014
The Journal of urology

FDG-positron emission tomography/computerized tomography for monitoring the response of pelvic lymph node metastasis to neoadjuvant chemotherapy for bladder cancer.

01-05-2013
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology

Response to induction chemotherapy and surgery in non-organ confined bladder cancer: a single institution experience.

01-04-2013
The Journal of urology

Carboplatin based induction chemotherapy for nonorgan confined bladder cancer--a reasonable alternative for cisplatin unfit patients?

01-10-2012
European journal of nuclear medicine and molecular imaging

18F-FDG PET/CT for monitoring induction chemotherapy in patients with primary inoperable penile carcinoma: first clinical results.

01-08-2010
Urologia internationalis

Pim1 regulates androgen-dependent survival signaling in prostate cancer cells.

11-03-2010

This site uses cookies

This website uses cookies to ensure you get the best experience on our website.